Cover Image


Ulcerative Colitis: KOL Insight

出版商 FirstWord 商品編碼 320356
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
瘍性大腸炎:KOL的洞察 Ulcerative Colitis: KOL Insight
出版日期: 2016年09月01日 內容資訊: 英文



  • 成藥
    • Uceris, Cortiment (Budesonide MMX; Cosmo/Santarus/Ferring)
  • 開發平台藥物
    • LT 02 (控制釋放卵磷脂; Lipid Therapeutics/Dr Falk Pharma/Nestle Health Science)


  • 成藥
    • TNF抑制劑
      • Remicade (Infliximab; Janssen Biotech/Merck & Co. /田邊三菱製藥)
      • Humira (Adalimumab; AbbVie/Eisai)
      • Simponi
    • TNK抑制劑的生技仿製藥
      • Remsima (Infliximab; Celltrion)
      • Inflectra (Infliximab; Hospira)
    • 其他
      • Entyvio (vedolizumab; Millennium/武田藥品工業)
  • 開發平台藥物
    • Etrolizumab (RG 7413, rhuMab beta7; Roche)
    • AJM 300 (Ajinomoto/Kissei)
    • Tofacitinib (CP 690550; Pfizer)
    • Ozanimod (RPC 1063; Celgene)
    • Kappaproct (cobitolimod, DIMS 0150; InDex Pharmaceuticals)
    • Alicaforsen (ISIS 2302; Atlantic Healthcare/Isis Pharmaceuticals)


Product Code: 596200640

Are UC biosimilars a real or perceived threat to branded drugs?

Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; first-mover, Entyvio has a direct competitor coming on stream; and there is even talk of combination therapies and natural treatments in some quarters. What are the most influential key opinion leaders (KOLs) saying about market dynamics for UC drug therapies? How do they expect the market to flex and adapt? Are the new arrivals likely to face an enthusiastic welcome or more of a tepid reception?

Covering 5 marketed drugs and 9 pipeline therapies, this report gives the viewpoint from 12 KOLs in North America and Europe. Find out what they think about prescribing trends for different patient segments, the various products coming through the pipeline, and the key issues influencing treatment choices.

Top Takeaways

“Fundamentally biosimilars are going to be a good thing, because it's going to drive costs down. There might be some minor differences clinically, but improving access of these drugs to the population far outweighs any clinical downside or scientific downside.” US Key Opinion Leader.

Sample of brands covered:

  • Uceris/Cortiment (budesonide MMX; Cosmo/Santarus/Ferring)
  • Entyvio (vedolizumab; Takeda)
  • Etrolizumab (RG 7413, rhuMab beta7; Roche)
  • Stelara (ustekinumab; Johnson & Johnson)
  • Plus 10 more

Sample of KOLS interviewed

  • Dr. Adam Cheifetz, MD, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School.
  • Prof Jean-Frédéric Colombel, MD, Professor of Medicine and Director of the Susan and Leonor Feinstein IBD Center at Icahn School of Medicine in New York, NY.
  • Prof Gerhard Rogler, MD, PhD, Professor of Gastroenterology and Hepatology and Ordinarius ad personam at the University of Zürich, based at the University hospital of Zurich.
  • Prof Laurent Peyrin-Biroulet, MD, PhD, Department of HepatoGastroenterology, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.
  • Plus 8 more - download the full list now >

Top Takeaways

  • Possible change to mild-to-moderate UC treatment: What difference will LT 02 (controlled-release phosphatidylcholine) make to entrenched 5-ASA prescribing habits? Do KOLs see LT 02 as an alternative or an add-on for early stage patients?
  • One brand is still the preferred TNF inhibitor, but for how long? How do gastroenterologists feel about switching to biosimilars and are they 100% confident about efficacy? Should originators be concerned for their market share?
  • Patient education: Is patient perception that non-branded drugs are inferior a real problem or a perceived one? Do KOLs believe pharma is helping or hindering patient views on biosimilars? Could (and should) more be done to educate patients about treatment choices?
  • Views on a crowded moderate-to-severe drug pipeline: One trial has recently halted but with 8 more still actively progressing, which hold most promise for KOLs? Conversely, which head-to-head trial is viewed as ‘risky' and which current study is described as ‘completely uninteresting'?
  • Two in-trial drugs are prompting more excitement than the rest: Which two potential new arrivals are viewed positively, but for different reasons? Could these be game changers for the severe patient segment?
  • Safety and cost dominate the debate: KOLs express cynicism about various pipeline drugs and possible treatment pathways, primarily due to side effect profiles and cost. The latter may also impact appetite for combination therapies, even though many KOLs are calling for this.
Back to Top